In this study, we investigated the presence of plasmid-mediated quinolone resistance (PMQR) genes among 101 ciprofloxacin-resistant urinary Escherichia coli isolates and searched for mutations in the quinolone-resistance-determining regions (QRDRs) of the DNA gyrase and topoisomerase IV genes in PMQR-carrying isolates. Eight isolates harboured the qnr and aac(6')-Ib-cr genes (3 qnrS1, 1 qnrB19 and 4 aac(6')-Ib-cr). A mutational analysis of the QRDRs in qnr and aac(6')-Ib-cr-positive isolates revealed mutations in gyrA, parC and parE that might be associated with high levels of resistance to quinolones. No mutation was detected in gyrB. Rare gyrA, parC and parE mutations were detected outside of the QRDRs. This is the first report of qnrB19, qnrS1 and aac(6')-Ib-cr -carrying E. coli isolates in Brazil.

No presente estudo, a produção de substâncias antagonistas por Lactobacillus murinus contra bactérias enteropatogênicas foi avaliada in vivo assim como um possível efeito protetor contra um desafio oral com Salmonella Typhimurium utilizando um modelo animal gnotobiótico. Um maior tempo médio de sobrevida (P < 0,05) foi observado nos animais associados com L. murinus (7,89 ± 3,83 dias) quando comparado com os controles (4,44 ± 0,73 dias). Lactobacillus murinus exerceu um potente efeito antagonista in vivo contra S. sonnei e com menos intensidade contra S. Typhimurium como revelado pelos halos de inibição ao redor das fezes dos animais associados com L. murinus. Os diâmetros dos halos de inibição ao redor dos conteúdos intestinais aumentaram ao longo do trato digestivo, seguindo proporcionalmente os níveis populacionais de L. murinus nas respectivas porções intestinais. Concluindo, o presente estudo mostra que a associação com L. murinus em camundongos gnotobióticos retarda a morte após um desafio oral com S. Typhimurium e que compostos inibitórios difusíveis obtidos em ensaios in vitro foram também produzidos in vivo e podem ser responsáveis por este efeito.

In the present study, production of antagonistic substances by Lactobacillus murinus against enteropathogenic bacteria was evaluated in vivo as well as a possible protective effect against an oral challenge with Salmonella Typhimurium using a gnotobiotic animal model. A higher mean survival time (P < 0.05) was observed in L. murinus-associated animals (7.89 ± 3.83 days) when compared with the control ones (4.44 ± 0.73 days). Lactobacillus murinus exerted a potent antagonistic effect in vivo against S. sonnei and to a lesser extent against S. Typhimurium as revealed by inhibitory halos around the feces of Lactobacillus-associated animals. Diameters of inhibitory halos around intestinal contents increased along the intestine tract, following proportionally the L. murinus population levels in the respective intestinal portions. Concluding, the present study showed that L. murinus association in gnotobiotic mice delayed the death after an oral challenge with S. Typhimurium and that inhibitory diffusible compounds obtained in in vitro assays were also produced in vivo and may be responsible for this effect.